Drugs / NTP42:KVA4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06092788 | Nov 2023 → Jan 2024 | — | ATXA Therapeutics Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NTP42:KVA4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06092788 ↗ |
| Route | Oral | “given NTP42:KVA4 in oral liquid form” NCT06092788 ↗ |